Helvacioglu et al. (2025) used Genomize-SEQ to identify a novel ACOX1 deletion in two cousins with PNALD, showing that adrenal insufficiency — previously associated mainly with whole-peroxisome assembly disorders — can also arise from a single broken peroxisomal enzyme.
Tzetis et al. (2025) identified a novel EHMT1 frameshift in a patient with Kleefstra syndrome with Genomize-SEQ, and showed that the affected protein domain predicts phenotypic severity — a finding with direct implications for clinical counseling.
Gürsoy et al. (2025) identified a genetic cause in 29% of children with unexplained intellectual disability through Genomize-SEQ targeted panel analysis — including three novel variants, one linked to a brain malformation never before associated with that gene.
Through Genomize-SEQ variant analysis, Bozkaya-Yilmaz et al. (2025) showed that CACNA1A mutations in 31 children can cause a wide range of neurological symptoms — from epilepsy and developmental delay to movement problems — even within the same family.
Tekin Orgun et al. (2025) used Genomize-SEQ to identify a rare ATP1A2 gene mutation in an infant with life-threatening, treatment-resistant seizures, showing that memantine — a drug that blocks overactivated brain receptors — stopped the seizures entirely when all standard therapies had failed.
Through Genomize-SEQ exome analysis, Sharif et al. (2025) found genetic mutations in 42% of men with unexplained infertility, revealing that sperm cell division gene mutations reliably predict failed surgical sperm retrieval — sparing patients from unnecessary procedures.
Yavas et al. (2025) used Genomize-SEQ to analyze whole-exome sequencing data from 50 Turkish patients with inherited eye diseases, identifying the genetic cause in 58% of cases — including six previously unknown variants — and pinpointing a likely common founder mutation in the ABCA4 gene within the Turkish population.
Erbilgin et al. (2026) used Genomize-SEQ to analyze targeted sequencing data from pediatric leukemia patients, finding that a key gene deletion (IKZF1) became more frequent at relapse — pointing to its role in treatment resistance rather than early disease prediction.
Yılmaz Uzman et al. (2025) used Genomize-SEQ to analyze targeted gene panel data from 149 children with suspected RASopathies, identifying disease-causing variants in over a quarter of patients and uncovering three new genetic variants — including rare clinical features never before described in these conditions.
Tezen et al. (2024) used Genomize-SEQ to analyze whole exome sequencing data from a multi-generational family, discovering that two rare nerve disorders, a neuromuscular junction defect and a hereditary neuropathy, were caused by separate gene mutations co-existing in the same family due to a history of consanguineous marriages.
